STAT+: Cancer medicines remain in short supply across the U.S., survey finds

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter.An ongoing shortage of cancer medications continues to force leading cancer centers around the U.S. to seek work-around strategies to treat patients and a majority also report that clinical trials have been disrupted, according to a new survey. All of the centers noted they are experiencing a shortage of at least one medicine, and more than 20% of the centers are currently reporting shortages of five or more different medications. The survey was conducted by the National Comprehensive Cancer Network, a nonprofit alliance of 34 treatment centers. Meanwhile, 61% reported they are able to treat patients despite shortages, but only by trying to avoid wasting medicines, limiting use of existing inventory and administering the minimum suggested dosing. Two-thirds of the centers also said shortages delay treatment, because they must again pursue prior authorization from insurers, the survey noted. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe